BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/17/2017 8:32:00 AM | Browse: 752 | Download: 1223
 |
Received |
|
2016-08-22 21:23 |
|
Peer-Review Started |
|
2016-08-24 08:50 |
|
To Make the First Decision |
|
2016-09-27 17:13 |
|
Return for Revision |
|
2016-10-08 09:58 |
|
Revised |
|
2016-10-23 16:13 |
|
Second Decision |
|
2017-01-04 15:56 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-01-14 14:30 |
|
Articles in Press |
|
2017-01-14 14:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-02-13 15:45 |
|
Publish the Manuscript Online |
|
2017-02-17 08:32 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Hiroto Wakabayashi, Shogo Ohkoshi, Takashi Tsukishiro, Toru Takahashi, Toshiaki Watanabe and Shuji Terai |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Grants-in-Aid for Scientific Research (C) (to Yamagiwa S) from Japan Society for the Promotion of Science (JSPS) |
15K08991 |
|
| Corresponding Author |
Satoshi Yamagiwa, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510,
Japan. syamagi@med.niigata-u.ac.jp |
| Key Words |
Telaprevir; Aged patients; Hepatitis C virus genotype 1b; Interleukin 28B; Simeprevir |
| Core Tip |
We evaluated the efficacy and safety of telaprevir (TVR)-and simeprevir (SMV)-based triple therapies for elderly patients with chronic hepatitis C, especially patients aged 66 years or older, in a real-world clinical setting. In both the TVR and SMV groups, no significant differences in the SVR and adverse events resulting in treatment discontinuation were found between the younger (aged ≤ 65) and older (aged > 65) patients. Both the TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with chronic hepatitis C virus genotype 1b infection. Ge-notyping of the interleukin-28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.
|
| Publish Date |
2017-02-17 08:32 |
| Citation |
Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i5/252.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i5.252 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
